joins
In a significant reform aimed at simplifying and catalysing corporate restructuring, the Fast Track Merger (FTM) route under Section 233 of the Companies Act, 2013, has been strengthened and expanded....
Over the past couple of months, the Central Drugs Standard Control Organisation has been actively streamlining licensing and approval requirements for pharmaceutical companies, with the aim of enhancing the ease of doing business in India. In addition, the Indian Council of Medical Research has further amended the National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017 to ensure that research involving traditional and modern medicine adheres to rigorous ethical and scientific standards. Other key developments such as the long-awaited ban by the Ministry of Health and Family Welfare on the use of chloramphenicol and nitrofurans in food-producing animal rearing systems and the decision by the High Court of Delhi to facilitate affordable treatment of Spinal Muscular Atrophy disease have dominated headlines in the space.
Against this backdrop, INDUSLAW’s Shantanu Jindel, Shweta Gupta, Kanika Sachdeva, Vatsal Agarwal, and Abhinav present you this edition of ‘Checking the Pulse’, delving into key updates from February 2025 to March 2025 in the healthcare and pharmaceutical sectors, while also tapping on notable deals that have gained interest from the industry
